| 10th week of 2015 patent applcation highlights part 52 |
| Patent application number | Title | Published |
|---|
| 20150064146 | Blood Brain Barrier Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 2015-03-05 |
| 20150064147 | CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION - Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. | 2015-03-05 |
| 20150064148 | METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION - The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1 | 2015-03-05 |
| 20150064149 | MATERIALS AND METHODS FOR CORRECTING RECESSIVE MUTATIONS IN ANIMALS - The present invention provides materials and methods for correcting an undesirable nucleic acid sequence (such as a deleterious recessive mutation) in the genome of animals (such as cattle) using site-specific nucleases to facilitate gene correction. In certain embodiments, the present invention can be used to correct mutations associated with a heritable disease selected from alpha-mannosidosis, beta-mannosidosis, arthrogryposis multiplex (AM), contractural arachnodactyly (CA), developmental duplication (DD), neuropathic hydrocephalus (NH), idiopathic epilepsy, osteopetrosis, protoporphyria, pulmonary hypoplasia and anasarca (PHA), titbial hemimelia (TH), Spider Lamb Syndrome (SLS), and Brisket Disease. | 2015-03-05 |
| 20150064150 | GENE THERAPY VECTORS FOR ADRENOLEUKODYSTROPHY AND ADRENOMYELONEUROPATHY - The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy. | 2015-03-05 |
| 20150064151 | CIRCADIAN RHYTHM-IMPROVING AGENT - The invention provides an agent for improving circadian rhythm comprising cells of lactic acid bacterium or treated product thereof as an active ingredient. | 2015-03-05 |
| 20150064152 | BIOPROTECTION USING LACTOBACILLUS PARACASEI STRAINS - The present invention is related to the field of bioprotection, in particular to the strain of | 2015-03-05 |
| 20150064153 | HIGH EFFICIENCY MICROFLUIDIC PURIFICATION OF STEM CELLS TO IMPROVE TRANSPLANTS - Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes. | 2015-03-05 |
| 20150064154 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. | 2015-03-05 |
| 20150064155 | METHODS FOR TREATMENT OF CERVICAL INSUFFICIENCY - Methods, compositions, devices and kits for increasing mechanical stiffness of an incompetent or a dilated biological tissue in a subject are provided herein. The methods described herein involve placing (e.g., injecting) a silk fibroin-based composition into at least a portion of an incompetent or dilated tissue of a subject. In some embodiments, the silk fibroin-based composition can further comprise at least two PEG components that will crosslink together upon placement (e.g., injection) into a subject in need thereof. In specific embodiments, the methods, compositions, devices and kits can be used to increase mechanical stiffness of a cervical tissue in a subject, for example, for treatment of cervical insufficiency. | 2015-03-05 |
| 20150064156 | CHIMERIC BACTERIOPHAGE LYSIN WITH ACTIVITY AGAINST STAPHYLOCOCCI BACTERIA - The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant | 2015-03-05 |
| 20150064157 | Lysosomal Targeting Peptides and Uses Thereof - The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor. | 2015-03-05 |
| 20150064158 | SENSE-IMPROVING AGENT - A purpose of the present invention is to provide a sense-improving agent which is safe and, when routinely taken or applied to the skin, exerts an effect of improving deterioration in peripheral sensation. Another purpose of the present invention is to provide a food, a drink, a feed or a cosmetic for improving sensation which exerts an effect of improving deterioration in peripheral sensation when orally taken or applied to the skin. The sense-improving agent comprises, as the active ingredient, a basic protein fraction derived from milk or a degraded basic protein fraction derived from milk. By orally taking the basic protein fraction derived from milk or the degraded basic protein fraction derived from milk or applying the same directly to the skin, deterioration in sensation, in particular, peripheral sensation can be improved. Thus, a food, a drink, a feed or a cosmetic for improving sensation can be obtained. | 2015-03-05 |
| 20150064159 | ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES - Methods and compositions relating to the engineering of an improved protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids. | 2015-03-05 |
| 20150064160 | ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS - Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids. | 2015-03-05 |
| 20150064161 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2015-03-05 |
| 20150064162 | MARKETING THE USE OF AN ACIDIC SOFT DRINK TO ENHANCE THE EFFICACY OF A GLUTEN-DIGESTING ENZYME - This invention relates to a method of marketing a gluten-digesting enzyme supplement comprising providing an effective amount of a gluten-digesting enzyme to a person desirous of maintaining or enhancing gastro intestinal comfort or delaying the onset of gastrointestinal discomfort; or desirous of reducing gluten exposure, and informing the gluten sensitive individuals of the ability to increase the efficacy of the supplement by drinking one serving of an acidic soft drink having a pH in a range from 2 to 3.5. Furthermore, it relates to a kit comprising a gluten-digesting enzyme supplement and instructions for use in combination with an acidic soft drink having a pH in a range from 2 to 3.5. | 2015-03-05 |
| 20150064163 | BMP Peptides & Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition. | 2015-03-05 |
| 20150064164 | TISSUE DISRUPTION TREATMENT AND COMPOSITION FOR USE THEREOF - The present invention relates to an agent having activity in the treatment of a tissue disruption. In particular the present invention relates to a composition comprising an effective amount of an active fraction having tissue healing properties | 2015-03-05 |
| 20150064165 | DEVICES AND METHODS FOR REDUCING THE APPEARANCE OF CELLULITE - Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae. | 2015-03-05 |
| 20150064166 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 2015-03-05 |
| 20150064167 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 2015-03-05 |
| 20150064168 | Cadherin-11 Inhibitors and Methods of Use Thereof - Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis. | 2015-03-05 |
| 20150064169 | PROTEASE-REGULATED ANTIBODIES - This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia. | 2015-03-05 |
| 20150064170 | Antibody Preparations - An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses. | 2015-03-05 |
| 20150064171 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE - The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R | 2015-03-05 |
| 20150064172 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. | 2015-03-05 |
| 20150064173 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. | 2015-03-05 |
| 20150064174 | NEUTRALIZING ANTIBODY FOR EPSTEIN BARR VIRUS-ASSOCIATED DISEASE - Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody. | 2015-03-05 |
| 20150064175 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC - A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells. | 2015-03-05 |
| 20150064176 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2015-03-05 |
| 20150064177 | THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN - The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury. | 2015-03-05 |
| 20150064178 | DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2015-03-05 |
| 20150064179 | HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof. | 2015-03-05 |
| 20150064180 | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier. | 2015-03-05 |
| 20150064181 | ANTISENSE CONJUGATES FOR DECREASING EXPRESSION OF DMPK - The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells. | 2015-03-05 |
| 20150064182 | STABILIZED SINGLE DOMAIN ANTIBODIES - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 2015-03-05 |
| 20150064183 | TARGETED THERAPEUTIC PROTEINS - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 2015-03-05 |
| 20150064184 | METHODS AND COMPOSITIONS FOR INCREASING ARYLSULFATASE A ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 2015-03-05 |
| 20150064185 | DRUG COMPOSITIONS, FUSHIONS AND CONJUGATES - Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent. | 2015-03-05 |
| 20150064186 | METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS - Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease. | 2015-03-05 |
| 20150064187 | FIBROSIS SUPPRESSION BY INHIBITING INTEGRIN ALPHA-8 BETA-1 FUNCTION - Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin α | 2015-03-05 |
| 20150064188 | POLYPEPTIDE STRUCTURAL MOTIFS ASSOCIATED WITH CELL SIGNALING ACTIVITY - Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing. | 2015-03-05 |
| 20150064189 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided. | 2015-03-05 |
| 20150064190 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 7R - Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors. | 2015-03-05 |
| 20150064191 | ANTI-C-MET-ANTIBODY FORMULATIONS - Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same. | 2015-03-05 |
| 20150064192 | MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS - Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided. | 2015-03-05 |
| 20150064193 | METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON-RESPONSE ALLELES - The disclosure is directed to predictive methods and personalized therapies for treating psoriatic arthritis (PsA). Specifically, this disclosure relates to methods of treating a patient having PsA by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the PsA patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods useful in predicting the likelihood that a patient having PsA will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. | 2015-03-05 |
| 20150064194 | Uses and Compositions for Treatment of Rheumatoid Arthritis - The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject. | 2015-03-05 |
| 20150064195 | USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS - The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject. | 2015-03-05 |
| 20150064196 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof - The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). | 2015-03-05 |
| 20150064197 | METHODS OF MODULATING IMMUNITY - The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration. | 2015-03-05 |
| 20150064198 | Enhancing Immunity to Tuberculosis - The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. | 2015-03-05 |
| 20150064199 | CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES - The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response. | 2015-03-05 |
| 20150064200 | METHODS AND COMPOSITIONS FOR 6-PHOSPHOGLUCONATE DEHYDROGENASE (6-PGD) AS A TARGET FOR LUNG CANCER THERAPY - The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing a proliferative disease that result in dysregulation of 6-phosphogluconate dehydrogenase. In particular, the methods and compositions include treatment of gefitinib/erlotinib resistant proliferative diseases such as lung cancer using a 6-phosphogluconate dehydrogenase antagonist. | 2015-03-05 |
| 20150064201 | ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM) - The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods. | 2015-03-05 |
| 20150064202 | HUMANIZED AND CHIMERIC ANTI-FACTOR C3 ANTIBODIES AND USES THEREOF - A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC. | 2015-03-05 |
| 20150064203 | ANTICANCER AGENT - According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody κ-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody κ-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence. | 2015-03-05 |
| 20150064204 | GITR ANTIGEN BINDING PROTEINS - Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a varienty of immunotherapy treatments, including treatment of various cancers and infections. | 2015-03-05 |
| 20150064205 | ENHANCEMENT OF PATHOGEN-SPECIFIC MEMORY TH17 CELL RESPONSES - Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections. | 2015-03-05 |
| 20150064206 | COMPOSITIONS FOR TREATING UVEITIS - Compositions including human Treg cells directed to an eye-associated antigen and methods for treating uveitis. | 2015-03-05 |
| 20150064207 | EPSILON TOXIN EPITOPES FROM CLOSTRIDIUM PERFRINGENS WITH REDUCED TOXICITY - There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by | 2015-03-05 |
| 20150064208 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran | 2015-03-05 |
| 20150064209 | METHODS FOR GENERATING IMMUNITY TO ANTIGEN - Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein. | 2015-03-05 |
| 20150064210 | HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME - Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers. | 2015-03-05 |
| 20150064211 | SYNTHETIC ACTIVE PEPTIDE FRAGMENTS - The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of | 2015-03-05 |
| 20150064212 | PROCESS FOR THE PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROIN ADDICTION - Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 Å, and methods of using the same. | 2015-03-05 |
| 20150064213 | Topical Composition For Treatment Of Skin, Hair And/Or Nails And Method Of Using The Same - A topical composition includes an amount of a concentrate derived from | 2015-03-05 |
| 20150064214 | DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES - A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. | 2015-03-05 |
| 20150064215 | THERAPEUTIC DELIVERY AND EXPRESSION SYSTEM, METHODS AND USES THEREOF - Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (IKDE) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium. The therapeutic factors include small interfering RNAs, tumoricidal proteins, DNA molecules, or a combination thereof. The system provides direct killing of tumor cells and alters the tumor microenvironment by expressing anti-angiogenic factors and cytokines in intracellular and/or extracellular environments. Also provided are methods of using natural exosomes comprising cargoes obtained from the bacterially infected cells. The bacteria-vector system is useful for many types of tumor and cancer as well as recombinant vaccines. The method causes significant regression of tumor and prolongs survival of tumor-bearing mice and subject without detectable systemic toxicity. | 2015-03-05 |
| 20150064217 | PLURIPOTENT GERM LAYER ORIGIN ANTIGEN PRESENTING CANCER VACCINE - The disclosure provides reagents, methods, and kits, for treating or preventing cancers derived from each of the germ layers (endoderm, mesoderm, ectoderm, neural crest). The reagent encompasses interferon-gamma (IFN-gamma) responsive cancer cells, where the cells are autophagic and non-apoptotic cancer cells, and where the cells express MHC Class II. | 2015-03-05 |
| 20150064218 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided. | 2015-03-05 |
| 20150064219 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY USING FLAGELLIN-TUMOR ASSOCIATED ANTIGEN FUSION PROTEIN EXPRESSING TUMOR CELLS - Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a NLR ligand and/or TLR ligand-TAA fusion protein or with an activated DC which has internalized a tumor cell which expresses an NLR- and/or TLR ligand-TAA fusion protein. | 2015-03-05 |
| 20150064220 | METHODS FOR MODULATING CELL-MEDIATED IMMUNITY USING HUMAN MILK OLIGOSACCHARIDES - Disclosed are methods of enhancing cell-mediated immunity in an individual using nutritional compositions including human milk oligosaccharides. The human milk oligosaccharides are sialylated human milk oligosaccharides, fucosylated human milk oligosaccharides, or a combination of both. The human milk oligosaccharides may enhance T-cell mediated responses and T-cell regulatory responses. | 2015-03-05 |
| 20150064221 | COMPOUNDS HAVING IMMUNOMUDULATOR ACTIVITY - The present invention is directed to methods of suppressing an immune response in a subject in need thereof comprising administering a therapeutically effective amount of a compound having the following formula: | 2015-03-05 |
| 20150064222 | NUTRITIONAL COMPOSITIONS FOR ENHANCING IMMUNE FUNCTION - The present disclosure relates to nutritional compositions for pediatric subjects, such as children's nutritional products and infant formulas, comprising a protein source, a fat source, and a source of β-1,3-glucan. | 2015-03-05 |
| 20150064223 | Biguanide Compositions and Methods of Treating Metabolic Disorders - Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 2015-03-05 |
| 20150064224 | Use of Certain Water-Insoluble Porous Polymeric Particles in Spherical Form as SPF Boosters - The present invention relates to a composition intended for protecting the skin and/or hair against ultraviolet radiation containing: (a) at least one photoprotective system capable of screening out UV radiation; and (b) water-insoluble polymeric porous particles in spherical form. | 2015-03-05 |
| 20150064225 | PHOTOPROTECTIVE COMPOSITION BASED ON A 2-ALKOXY-4-ALKYL KETONE PHENOL COMPOUND; USE OF SAID COMPOUND FOR INCREASING THE SUN PROTECTION FACTOR - The present invention relates to a fluid composition intended for protecting the skin and/or hair against ultraviolet radiation, characterized by the fact that it comprises, in a cosmetically acceptable aqueous support, at least: (a) one photoprotective system capable of screening out UV radiation; and (b) one 2-alkoxy-4-alkyl ketone phenol compound. The present invention also relates to the use of a 2-alkoxy-4-alkyl ketone phenol compound in a composition comprising, in a cosmetically acceptable medium, at least one photoprotective system capable of screening out UV radiation. | 2015-03-05 |
| 20150064226 | Insecticide-Containing Netlike Fabric - The present invention relates to an insecticide-containing fabric containing at least one embedded insecticidally active ingredient in the polymeric matrix and having excellent wash resistance, and also to the products produced from this fabric and to their use for protecting humans, animals and plants against arthropods, particularly for controlling insects. | 2015-03-05 |
| 20150064227 | Sporicidal Formulation Including Botanical Extracts/Botanical-Derived Ingredients - Formulations and wipes for imparting a sporicide to a surface are disclosed herein. Unexpectedly, a set of naturally derived ingredients have been found to combat and treat spore-based bacteria without the use of harsh chemicals. To achieve the sporicidal efficacy of the product, botanical extracts and/or botanical-derived ingredients have been incorporated into a sporicidal formulation. Example botanical extracts that demonstrated sporicidal activity include: | 2015-03-05 |
| 20150064228 | METHOD FOR TREATING BIOLOGICAL TISSUE AND BIOLOGICAL TISSUE - The present invention suppresses the strength reduction or degeneration of a tissue after the tissue is dried and/or sterilized, for the tissue comprising biological components and the like. Specifically, biological tissue is immersed in a trehalose solution and shaken, thereby impregnating the biological tissue with the trehalose solution. The trehalose solution used here is one obtained by dissolving trehalose in a phosphate buffered saline, the concentration of trehalose being preferably in the range of 20 wt % to 35 wt %. Thereafter, the biological tissue is dried to remove moisture in the biological tissue, and sterilized with ethylene oxide gas. | 2015-03-05 |
| 20150064229 | BIOACTIVE POROUS BONE GRAFT IMPLANTS - Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling. | 2015-03-05 |
| 20150064230 | SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS - The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye. | 2015-03-05 |
| 20150064231 | Oral film containing opiate enteric-release beads - A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines. | 2015-03-05 |
| 20150064232 | TRANSDERMAL ABSORPTION PREPARATION - [Problem] To provide a transdermal absorption preparation exhibiting excellent transdermal absorbability for 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof. | 2015-03-05 |
| 20150064233 | LIPID-COATED NUCLEIC ACID NANOSTRUCTURES OF DEFINED SHAPE - The invention provides nanoparticles containing a nucleic acid nanostructure, of defined shape and size, linked to a hydrophobic moiety and coated by lipids, compositions comprising the nanoparticles, and methods of producing and methods of using the nanoparticles. | 2015-03-05 |
| 20150064234 | 4-AMINOPYRIDINE AS A THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY - It has been discovered that pharmacological inhibition of K+ channels (using the FDA-approved broad-spectrum K+ channel antagonist 4-AP) positively benefitted smn mutant phenotypes, a result that is consistent with the defective excitability of motor circuits by their interneuron or sensory neuron inputs being a critical consequence of SMN depletion. Based on these observations, certain embodiments of the invention are directed to methods of treatment of SMA by administering therapeutically effective amounts of one or more potassium channel antagonists, including 4-aminopyridine, 4-(dimethylamino)pyridine, 4-(methylamino)pyridine, and 4-(aminomethyl)pyridine. Other embodiments are directed to new pharmaceutical formulations comprising two or more potassium channel antagonists. | 2015-03-05 |
| 20150064235 | MODIFIED POLYNUCLEOTIDES - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2015-03-05 |
| 20150064236 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2015-03-05 |
| 20150064237 | MEDICINAL COMPOSITION FOR TREATING INFARCTION - The present invention provides a pharmaceutical composition for treating infarction, such as myocardial infarction or cerebral infarction, with a method that is different from conventional therapeutic methods that use a thrombolytic agent or balloon therapy. | 2015-03-05 |
| 20150064238 | METHOD AND COMPOSITION FOR ENHANCING THE DELIVERY OF ANTI-PLATELET DRUGS FOR THE TREATMENT OF ACUTE STROKE - The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by, administration of a high dose of the anti-platelet drugs. The invention also provides a pharmaceutical composition for enhancing treatment of acute stroke and a method for treating acute stroke using the pharmaceutical composition of the invention. | 2015-03-05 |
| 20150064239 | METHODS FOR IDENTIFYING MODULATORS OF IL-24 MEDIATED APOPTOSIS AND IMMUNOTHERAPY - A method for identifying modulators of Interleukin 24 (IL-24) mediated apoptosis is disclosed. For IL-24 apoptosis to be effective, the cells should express Sigma 1 Receptor (S1R). Additionally apoptosis modulators can be identified by exposing biological cells to test compounds and monitoring for signs of endoplasmic reticulum (ER) stress protein expression; calcium mobilization; or reactive oxygen species (ROS) production. | 2015-03-05 |
| 20150064240 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant - Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer. | 2015-03-05 |
| 20150064241 | Delivery of Functionalized Particles - A device includes a capsule sized to pass through a lumen of a gastrointestinal tract, a plurality of functionalized particles disposed within the capsule, one or more tissue penetrating members configured to puncture a wall of the lumen of the intestinal tract; and an actuator having a first configuration and a second configuration. The actuator is configured to retain the plurality of functionalized particles within the capsule in the first configuration. The actuator is further configured to advance the plurality of functionalized particles from the capsule into a wall of the lumen of the gastrointestinal tract via the one or more tissue penetrating members by the actuator transitioning from the first configuration to the second configuration. Systems including the device and methods of delivering functionalized particles to the body are also provided. | 2015-03-05 |
| 20150064242 | TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. | 2015-03-05 |
| 20150064243 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMININISTRATION OF HYDROPHOBIC DRUGS - Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided. | 2015-03-05 |
| 20150064244 | KONJAC FORMULATION AND METHOD FOR PREPARING THE SAME - A konjac formulation in the form of a capsule, including between 85 and 95 parts by weight of konjac gum, between 5 and 10 parts by weight of black rice, between 0.5 and 2 parts by weight of biological Fe, and between 0.5 and 2 parts by weight of vitamin. | 2015-03-05 |
| 20150064245 | Abuse Resistant Forms of Immediate Release Hydromorphone, Method of Use and Method of Making - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2015-03-05 |
| 20150064246 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE OXYMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2015-03-05 |
